Pharos iBio Statistics

Total Valuation

Pharos iBio has a market cap or net worth of KRW 127.78 billion. The enterprise value is 119.14 billion.

Market Cap	127.78B
Enterprise Value	119.14B

Important Dates

The next estimated earnings date is Tuesday, March 17, 2026.

Earnings Date	Mar 17, 2026
Ex-Dividend Date	n/a

Share Statistics

Pharos iBio has 12.95 million shares outstanding. The number of shares has increased by 0.13% in one year.

Current Share Class	12.95M
Shares Outstanding	12.95M
Shares Change (YoY)	+0.13%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	32.95%
Owned by Institutions (%)	1.93%
Float	8.68M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	11.21
P/TBV Ratio	11.61
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-12.13
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-13.84

Financial Position

The company has a current ratio of 11.32, with a Debt / Equity ratio of 0.02.

Current Ratio	11.32
Quick Ratio	10.97
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	-0.03
Interest Coverage	-1,336.65

Financial Efficiency

Return on equity (ROE) is -61.86% and return on invested capital (ROIC) is -44.64%.

Return on Equity (ROE)	-61.86%
Return on Assets (ROA)	-42.99%
Return on Invested Capital (ROIC)	-44.64%
Return on Capital Employed (ROCE)	-99.34%
Weighted Average Cost of Capital (WACC)	3.04%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +22.15% in the last 52 weeks. The beta is -0.22, so Pharos iBio's price volatility has been lower than the market average.

Beta (5Y)	-0.22
52-Week Price Change	+22.15%
50-Day Moving Average	9,328.60
200-Day Moving Average	6,933.68
Relative Strength Index (RSI)	48.04
Average Volume (20 Days)	629,831

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	-14.08M
Operating Income	-11.49B
Pretax Income	-9.82B
Net Income	-9.82B
EBITDA	-10.65B
EBIT	-11.49B
Earnings Per Share (EPS)	-759.07

Full Income Statement

Balance Sheet

The company has 8.89 billion in cash and 249.99 million in debt, with a net cash position of 8.64 billion or 667.21 per share.

Cash & Cash Equivalents	8.89B
Total Debt	249.99M
Net Cash	8.64B
Net Cash Per Share	667.21
Equity (Book Value)	11.40B
Book Value Per Share	880.34
Working Capital	8.45B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -8.27 billion and capital expenditures -336.54 million, giving a free cash flow of -8.61 billion.

Operating Cash Flow	-8.27B
Capital Expenditures	-336.54M
Free Cash Flow	-8.61B
FCF Per Share	-665.12

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Pharos iBio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.13%
Shareholder Yield	-0.13%
Earnings Yield	-7.69%
FCF Yield	-6.74%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1